Experimental Study on Therapeutic Effect of in Vivo Expression of Cell I-Hep II Recombinant Polypeptide of Fibronectin on Murine H22 Hepatocellular Carcinoma

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2003 Sep 13

PMID 12970880

Citations 2

Authors

Gui-Mei Zhang

Yan Yang

Bo Huang

Hui Xiao

Dong Li

Zuo-Hua Feng

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the inhibitory effect of in vivo expression of expressing plasmid pCH510 of recombinant fibronectin polypeptide (CH50) on hepatocellular carcinoma and the improved therapeutic effect of pCH510 in combination with chemotherapeutic agents and Hsp70-H22 hepatocarcinoma antigen peptide on tumor.

Methods: Mice were inoculated with H22 hepatocarcinoma cells. The chemotactic effect of the expression of plasmid pCH510 on immunocytes was observed after in vivo transfection, tissue slicing and HE staining. Inhibitory effect of transfection with pCH510 on murine tumor originated from different inoculative doses was observed. The inhibitory effect of immediate transfection with pCH510 after chemotherapy on tumor was compared with that of transfection 5 days after chemotherapy. The change of function and amount of mouse peritoneal macrophages and the peripheral blood immunocytes resulted from administration of chemotherapeutic agents were detected. The peptides mixture was prepared from H22 hepatocarcinoma cells. pCH510 + Hsp70-H22 antigen peptides were injected into tumor-bearing mice with or without chemotherapy, to observe the inhibitory effects on tumor.

Results: At the tumor tissue site injected with pCH510, there were a great number of immunocytes which mainly were macrophages, lymphocytes and neutrophils. Transfection of plasmid pCH510 inhibited significantly the murine tumor induced by different inoculative doses. The inhibitory effect was negatively correlated with the inoculative dose. The therapeutic effect was not improved by immediate transfection with pCH510 after chemotherapy, but was significantly improved by transfection with pCH510 5 days after chemotherapy. Chemotherapeutic agent decreased the number of immunocytes and suppressed their activation in vivo. After injection of drug, the amount of immunocytes was the lowest from d 1 to d 3 and returned to normal level on the 10(th) day. Transfection with plasmid pCH510 alone could inhibit tumor induced by the inoculation with 10(4) H22 cells. The tumor originated from the inoculation with 10(5) H22 cells was inhibited by pCH510+Hsp70-H22 antigen peptides and that from the inoculation with 10(6) H22 cells was inhibited by pCH510+Hsp70-H22 antigen peptides in combination with chemotherapeutic agents.

Conclusion: In vivo expression of pCH510 recruits immune cells, inhibits tumor growth, and enhances the efficacy of chemotherapy. But the proper timing of combining chemotherapy with pCH510 must be taken into great account. The synergism of pCH510 and Hsp70-H22 peptides can improve the efficacy, which could be further enhanced if they are used following chemotherapy. Chemotherapeutic agent + pCH510 + Hsp70-H22 peptides is a promising therapeutic approach of combination treatment of tumor.

Citing Articles

Inhibitory effect of recombinant fibronectin polypeptide CH50 on invasion and metastasis of melanoma B16 cells.

Wei J, Xiong Y J Huazhong Univ Sci Technolog Med Sci. 2007; 27(1):17-9.

PMID: 17393099 DOI: 10.1007/s11596-007-0105-2.

U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3.

Ifon E, Pang A, Johnson W, Cashman K, Zimmerman S, Muralidhar S Cancer Cell Int. 2005; 5:19.

PMID: 15972109 PMC: 1200560. DOI: 10.1186/1475-2867-5-19.

References

Ng C, Bonavida B . A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Adv Cancer Res. 2002; 85:145-74. DOI: 10.1016/s0065-230x(02)85005-9. View

Markowicz S, Skurzak H, Walewski J . A method for directly determining the number of dendritic cells and for evaluation of their function in small amounts of human peripheral blood. Arch Immunol Ther Exp (Warsz). 2001; 49(1):51-7. View

Fan J, Wu Z, Tang Z, Zhou J, Qiu S, Ma Z . Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein. World J Gastroenterol. 2002; 7(1):28-32. PMC: 4688696. DOI: 10.3748/wjg.v7.i1.28. View

Castelli C, Ciupitu A, Rini F, Rivoltini L, Mazzocchi A, Kiessling R . Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res. 2001; 61(1):222-7. View

van Golen K, Bao L, Brewer G, Pienta K, Kamradt J, Livant D . Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. Neoplasia. 2002; 4(5):373-9. PMC: 1564117. DOI: 10.1038/sj.neo.7900258. View

Hanahan D, Bergers G, Bergsland E . Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000; 105(8):1045-7. PMC: 300842. DOI: 10.1172/JCI9872. View

Saiki I, Yoneda J, Kobayashi H, Igarashi Y, Komazawa H, Ishizaki Y . Antimetastatic effect by anti-adhesion therapy with cell-adhesive peptide of fibronectin in combination with anticancer drugs. Jpn J Cancer Res. 1993; 84(3):326-35. PMC: 5919152. DOI: 10.1111/j.1349-7006.1993.tb02874.x. View

Saito N, Mitsuhashi M, Hayashi T, Narumo C, Nagata H, Soyama K . Inhibition of hepatic metastasis in mice treated with cell-binding domain of human fibronectin and angiogenesis inhibitor TNP-470. Int J Clin Oncol. 2001; 6(5):215-20. DOI: 10.1007/pl00012108. View

Harler M, Wakshull E, Filardo E, ALBINA J, Reichner J . Promotion of neutrophil chemotaxis through differential regulation of beta 1 and beta 2 integrins. J Immunol. 1999; 162(11):6792-9. View

10.

Shi M, Wang F, Wu Z . Synergetic anticancer effect of combined quercetin and recombinant adenoviral vector expressing human wild-type p53, GM-CSF and B7-1 genes on hepatocellular carcinoma cells in vitro. World J Gastroenterol. 2003; 9(1):73-8. PMC: 4728253. DOI: 10.3748/wjg.v9.i1.73. View

11.

Wang X, Liu F, Li X, Li J . Retrovirus-mediated gene transfer of human endostatin inhibits growth of human liver carcinoma cells SMMC7721 in nude mice. World J Gastroenterol. 2002; 8(6):1045-9. PMC: 4656377. DOI: 10.3748/wjg.v8.i6.1045. View

12.

Liu J, Tang Y, Shen Y, Zhong X . Synergistic effect of cell differential agent-II and arsenic trioxide on induction of cell cycle arrest and apoptosis in hepatoma cells. World J Gastroenterol. 2003; 9(1):65-8. PMC: 4728251. DOI: 10.3748/wjg.v9.i1.65. View

13.

Tamura Y, Peng P, Liu K, Daou M, Srivastava P . Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science. 1997; 278(5335):117-20. DOI: 10.1126/science.278.5335.117. View

14.

Hanau D, Spehner D, Schmid C, Rammensee H, de la Salle H, Schild H . Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol. 1999; 162(7):3757-60. View

15.

Ruiz J, Mazzolini G, Sangro B, Qian C, Prieto J . Gene therapy of hepatocellular carcinoma. Dig Dis. 2002; 19(4):324-32. DOI: 10.1159/000050699. View

16.

Blachere N, Li Z, Chandawarkar R, Suto R, Jaikaria N, Basu S . Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med. 1997; 186(8):1315-22. PMC: 2199095. DOI: 10.1084/jem.186.8.1315. View

17.

Wu Y, Wan Y, Bian J, Zhao J, Jia Z, Zhou L . Phage display particles expressing tumor-specific antigens induce preventive and therapeutic anti-tumor immunity in murine p815 model. Int J Cancer. 2002; 98(5):748-53. DOI: 10.1002/ijc.10260. View

18.

Yoneda J, Saiki I, Kobayashi H, Fujii H, Ishizaki Y, Kato I . Inhibitory effect of recombinant fibronectin polypeptides on the adhesion of liver-metastatic lymphoma cells to hepatic sinusoidal endothelial cells and tumor invasion. Jpn J Cancer Res. 1994; 85(7):723-34. PMC: 5919543. DOI: 10.1111/j.1349-7006.1994.tb02421.x. View

19.

Mohr L, Geissler M, Blum H . Gene therapy for malignant liver disease. Expert Opin Biol Ther. 2002; 2(2):163-75. DOI: 10.1517/14712598.2.2.163. View

20.

Shi B, Wang X, Mu Q, Wu T, Liu H, Yang Z . Angiogenesis effect on rat liver after administration of expression vector encoding vascular endothelial growth factor D. World J Gastroenterol. 2003; 9(2):312-5. PMC: 4611336. DOI: 10.3748/wjg.v9.i2.312. View